Evidence map›Paper›PMID 36358193›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Next-Generation Sequencing of Carbapenem-Resistant

Ján Koreň, Michal Andrezál, Hana Drahovská, Zuzana Hubenáková, Adriána Liptáková, Tibor Maliar

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pathogens (Basel, Switzerland) · 2024
    Pooled it
  3. Incidence of carbapenemase-resistant isolates ofNew microbes and new infections · 2026
    Article
  4. Article
  5. Frontiers in microbiology · 2024
    Article
  6. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Article
  9. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ján KoreňInstitute of Microbiology, Faculty of Medicine, Comenius University, University Hospital Bratislava, 81108 Bratislava, Slovakia.
Michal AndrezálDepartment of Molecular Biology, Faculty of Natural Sciences, Comenius University, 84215 Bratislava, Slovakia.
Hana DrahovskáDepartment of Molecular Biology, Faculty of Natural Sciences, Comenius University, 84215 Bratislava, Slovakia.
Zuzana HubenákováInstitute of Microbiology, Faculty of Medicine, Comenius University, University Hospital Bratislava, 81108 Bratislava, Slovakia.
Adriána LiptákováInstitute of Microbiology, Faculty of Medicine, Comenius University, University Hospital Bratislava, 81108 Bratislava, Slovakia.ORCID 0000-0002-1677-0590
Tibor MaliarDepartment of Biotechnologies, Faculty of Natural Sciences, University of SS. Cyril and Methodius in Trnava, 91701 Trnava, Slovakia.

Funding

European Regional Development Fund ITMS: 313011T431European Structural and Investment Funds NFP313010V344Slovak Research and Development Agency SRDA-20-0413
6 · The paper itself

Abstract

Carbapenem-resistant (CR)

Indexed as

antimicrobial resistancecarbapenem-resistant Klebsiella pneumoniaecgMLSThealthcare facilities

Identifiers

PMID36358193
PMCPMC9686475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.